Alice Berger, PhD


Alice Berger, PhD

Associate Professor
Human Biology Division, Fred Hutch

Associate Professor, Herbold Computational Biology Program
Public Health Sciences Division, Fred Hutch

Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch

Mail Stop: C2-023

Dr. Alice Berger is an expert in discovering how changes to our genetic code lead to cancer. She works to translate these insights into new drug targets and biomarkers to benefit patients. Deep examinations of the genetic code in tumors highlight many mutations, or alterations in DNA sequence — but it’s not always clear which mutations are important or how they will affect the function of the protein encoded by the altered gene. Dr. Berger has developed methods that help assess both the functional consequences of gene alterations and how these changes lead to cancer. In particular, she focuses on lung adenocarcinoma and the role that changes to a gene called RIT1 play in tumor formation. By better understanding the function of RIT1 and the molecular pathways it regulates, Dr. Berger hopes to discover possible targets for new therapies.


Cornell University, Weill Graduate School of Medical Sciences, 2011, PhD

University of Virginia, 2003, BS (Chemistry)

Research Interests

The goal of the Berger laboratory is to enable precision medicine by systematically uncovering the molecular alterations in cancer, determining the function of these variant alleles, and understanding how these alleles modulate response to targeted or immune-based therapies. Although many of the genes involved in cancer have now been identified, a major challenge is discovering which specific alleles of these genes are involved and how these alleles modulate therapeutic response. We combine functional genomics, computational biology, biochemistry, and genetics to understand the mechanism of somatic cancer variants. Our goal is to identify drug targets and biomarkers and to translate this knowledge into clinical benefit for patients.

Current Studies

The current goals of the laboratory are two-fold: to develop better high-throughput systems for interrogation of variant allele function at scale, and to investigate the mechanisms of cancer oncogenes.

Gene expression-based phenotyping of variant alleles. Genome analysis is increasingly relied on for diagnostic and therapeutic care, but most cancer-associated variants are of unknown significance. Our lab has pioneered the use of high-throughput methods to determine the allele-by-allele function of genetic variants. We are using single cell RNA-seq to profile the consequences of hundreds of somatic mutations in parallel and to develop new methods to infer mutation impact directly from tumor expression data.

Mechanism and targeting of cancer oncogenes. Both KRAS and RIT1 encode small GTPase proteins and are mutated in lung adenocarcinoma and in the germline of “Ras-opathy” patients. Although KRAS has been extensively studied, RIT1 mutations were discovered only recently and the role of these mutations in cancer is poorly understood. We are using unbiased proteomic approaches and genome-wide CRISPR knockout screens to determine the functional similarities and differences between KRAS and RIT1, with the goal of identifying critical effectors of these proteins that might be targeted for therapeutic benefit.

"...Learning how normal cell biology gets messed up, you can also learn something about how [cells function] normally. I thought that was a really interesting way to learn about genetics and cell biology."

— Dr. Alice Berger

Find a Clinical Trial

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email or call 206.667.2210